Do analysts prefer FNCH or VERU?

Veru has a consensus target price of $24.50, suggesting a potential upside of 828.03%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is FNCH or VERU more profitable?

Veru's return on equity of -47.58% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Veru N/A -47.58% -35.83%

Which has preferable earnings & valuation, VIRI or FNCH?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is VIRI or FNCH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts rate FNCH or GRCE?

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 185.71%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, FNCH or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is FNCH or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Grace Therapeutics N/A -36.11% -34.39%

Do analysts prefer FNCH or ATHE?

Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 120.26%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, FNCH or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Is FNCH or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Alterity Therapeutics N/A N/A N/A

Finch Therapeutics Group (FNCH) Competitors

$7.30 0.00 (0.00%)

As of 09/4/2026

Compare

FNCH vs. VERU, VIRI, GRCE, KPTI, and ATHE

Should you buy Finch Therapeutics Group stock or one of its competitors? Finch Therapeutics Group's main competitors and comparable companies include Veru (VERU), Virios Therapeutics (VIRI), Grace Therapeutics (GRCE), Karyopharm Therapeutics (KPTI), and Alterity Therapeutics (ATHE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Finch Therapeutics Group compare to Veru?

Finch Therapeutics Group (NASDAQ:FNCH) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Veru had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Veru and 0 mentions for Finch Therapeutics Group. Veru's average media sentiment score of 0.34 beat Finch Therapeutics Group's score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Veru	Neutral

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Veru has higher revenue and earnings than Finch Therapeutics Group. Veru is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Veru	$16.89M	2.67	-$22.73M	-$0.69	N/A

Veru has a consensus target price of $24.50, suggesting a potential upside of 828.03%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veru's return on equity of -47.58% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Veru	N/A	-47.58%	-35.83%

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, indicating that its stock price is 217% less volatile than the broader market.

Summary

Veru beats Finch Therapeutics Group on 10 of the 14 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Finch Therapeutics Group's return on equity of -69.14% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Finch Therapeutics Group	Neutral

Summary

Finch Therapeutics Group beats Virios Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Grace Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 10.8% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

In the previous week, Grace Therapeutics had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled Grace Therapeutics'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Grace Therapeutics	Neutral

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Grace Therapeutics' return on equity of -36.11% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Grace Therapeutics	N/A	-36.11%	-34.39%

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 185.71%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Grace Therapeutics beats Finch Therapeutics Group on 7 of the 12 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Karyopharm Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 542.46%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Karyopharm Therapeutics is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Karyopharm Therapeutics had 9 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 9 mentions for Karyopharm Therapeutics and 0 mentions for Finch Therapeutics Group. Karyopharm Therapeutics' average media sentiment score of 0.12 beat Finch Therapeutics Group's score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Finch Therapeutics Group	Neutral

Finch Therapeutics Group has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Finch Therapeutics Group has lower revenue, but higher earnings than Karyopharm Therapeutics. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.28	-$196.04M	-$13.09	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Karyopharm Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Summary

Karyopharm Therapeutics beats Finch Therapeutics Group on 10 of the 16 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Alterity Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Finch Therapeutics Group. Alterity Therapeutics' average media sentiment score of 0.13 beat Finch Therapeutics Group's score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Alterity Therapeutics	Neutral

Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 120.26%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alterity Therapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats Finch Therapeutics Group on 8 of the 11 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FNCH vs. The Competition

Export

Metric	Finch Therapeutics Group	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.72M	$12.25B	$7.25B	$12.92B
Dividend Yield	N/A	2.58%	2.53%	9.14%
P/E Ratio	-0.83	792.20	273.54	25.43
Price / Sales	N/A	754.62	630.11	96.68
Price / Cash	N/A	90.26	77.08	52.44
Price / Book	0.51	12.47	12.85	6.17
Net Income	-$74.75M	$2.83B	$3.49B	$350.08M
7 Day Performance	N/A	4.03%	1.04%	-0.14%
1 Month Performance	N/A	6.29%	5.52%	1.02%
1 Year Performance	-42.52%	9.93%	24.39%	14.51%

Finch Therapeutics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
VERU Veru	2.7108 of 5 stars	$2.70 +1.9%	$24.50 +807.4%	-20.0%	$46.04M	$16.89M	N/A	230	Analyst Upgrade
VIRI Virios Therapeutics	N/A	$2.36 -4.8%	N/A	-52.1%	$45.45M	N/A	N/A	5
GRCE Grace Therapeutics	1.4472 of 5 stars	$2.10 -1.9%	$6.00 +185.7%	-31.4%	$44.21M	N/A	N/A	N/A	News Coverage
KPTI Karyopharm Therapeutics	2.6605 of 5 stars	$1.82 +2.5%	$11.50 +533.6%	-73.4%	$41.16M	$146.07M	N/A	380	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. VERU, VIRI, GRCE, KPTI, and ATHE

How does Finch Therapeutics Group compare to Veru?

Summary

How does Finch Therapeutics Group compare to Virios Therapeutics?

Summary

How does Finch Therapeutics Group compare to Grace Therapeutics?

Summary

How does Finch Therapeutics Group compare to Karyopharm Therapeutics?

Summary

How does Finch Therapeutics Group compare to Alterity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. VERU, VIRI, GRCE, KPTI, and ATHE

How does Finch Therapeutics Group compare to Veru?

Does the media prefer FNCH or VERU?

Do insiders and institutionals hold more shares of FNCH or VERU?

Which has stronger earnings and valuation, FNCH or VERU?

Do analysts prefer FNCH or VERU?

Is FNCH or VERU more profitable?

Which has more risk and volatility, FNCH or VERU?

Summary

How does Finch Therapeutics Group compare to Virios Therapeutics?

Is VIRI or FNCH more profitable?

Which has more risk and volatility, VIRI or FNCH?

Do insiders and institutionals have more ownership in VIRI or FNCH?

Which has preferable earnings & valuation, VIRI or FNCH?

Does the media refer more to VIRI or FNCH?

Summary

How does Finch Therapeutics Group compare to Grace Therapeutics?

Do insiders and institutionals have more ownership in FNCH or GRCE?

Which has stronger valuation & earnings, FNCH or GRCE?

Does the media refer more to FNCH or GRCE?

Which has more volatility & risk, FNCH or GRCE?

Is FNCH or GRCE more profitable?

Do analysts rate FNCH or GRCE?

Summary

How does Finch Therapeutics Group compare to Karyopharm Therapeutics?

Do insiders & institutionals believe in KPTI or FNCH?

Do analysts rate KPTI or FNCH?

Does the media favor KPTI or FNCH?

Is KPTI or FNCH more profitable?

Which has higher earnings and valuation, KPTI or FNCH?

Which has more volatility & risk, KPTI or FNCH?

Summary

How does Finch Therapeutics Group compare to Alterity Therapeutics?

Does the media refer more to FNCH or ATHE?

Do analysts prefer FNCH or ATHE?

Which has better earnings & valuation, FNCH or ATHE?

Which has more risk & volatility, FNCH or ATHE?

Do institutionals & insiders hold more shares of FNCH or ATHE?

Is FNCH or ATHE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools